Ongoing Investigation: Medpace Holdings, Inc. (MEDP) May Have Misled Shareholders - Levi & Korsinsky Investigates

New York, New York--(Newsfile Corp. - February 23, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Medpace Holdings, Inc. ("Medpace Holdings, Inc.") (NASDAQ: MEDP) concerning potential violations of the federal securities laws. On February 10, 2026, Medpace shares fell approximately 10% by mid-day and closed down 15.9%, according to data from Quiver Quantitative and GuruFocus.

Newsfile Corp • Feb 23, 2026

Medpace Holdings Under Investigation After Book-to-Bill Miss Exposes Cancellation Surge and Pipeline Fragility

(NASDAQ: MEDP) NEW YORK, Feb. 18, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP is investigating Medpace Holdings, Inc. (NASDAQ: MEDP) concerning potential securities law claims on behalf of shareholders. The investigation centers on whether the company and its senior officers made statements about the health of its clinical-trial booking pipeline that were inconsistent with internal data showing elevated cancellation rates and a deteriorating book-to-bill ratio.

PRNewsWire • Feb 18, 2026

Lost Investment in Medpace Holdings, Inc. (MEDP)? Levi & Korsinsky Launches Securities Fraud Investigation

New York, New York--(Newsfile Corp. - February 17, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Medpace Holdings, Inc. ("Medpace Holdings, Inc.") (NASDAQ: MEDP) concerning potential violations of the federal securities laws. On February 10, 2026, Medpace shares fell approximately 10% by mid-day and closed down 15.9%, according to data from Quiver Quantitative and GuruFocus.

Newsfile Corp • Feb 17, 2026

Why Big Stock Swings Like Medpace's 55% Jump Usually Have Clear Causes--Not Market Madness

Large, sudden stock price swings—like Medpace's recent spike and drop—are often driven by identifiable factors such as short squeezes or concentrated trading, not pure randomness. Investors should distinguish between moves based on verifiable corporate developments and those fueled by momentum or retail trading, as each carries different risks and implications for long-term value.

The Motley Fool • Feb 16, 2026

Zelluna selects Medpace as CRO for ZIMA-101 first-in-human clinical trial

Oslo, Norway – 11 February 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announced a clinical partnership with Medpace, a leading global Contract Research Organization (CRO), to support the first clinical trial of ZI-MA4-1 (ZIMA-101), Zelluna's lead product candidate.

GlobeNewsWire • Feb 11, 2026

The 'Key Negative' That Took Out Medpace's Sales, Profit Beat

Medpace stock slumped early Tuesday on a "significant bookings miss," outshining the company's solid fourth-quarter sales and earnings.

Investors Business Daily • Feb 10, 2026

Medpace Holdings, Inc. (MEDP) Q4 2025 Earnings Call Transcript

Medpace Holdings, Inc. (MEDP) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 10, 2026

Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Results

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Results Revenue for the three months ended December 31, 2025 increased 32.0% to $708.5 million, compared to $536.6 million for the comparable prior-year period. On a constant currency basis, revenue for the fourth quarter of 2025 increased 31.4% compared to the fourth quarter of 2024. Backlog.

Business Wire • Feb 9, 2026

Medpace (MEDP) Beats Q4 Earnings and Revenue Estimates

Medpace (MEDP) came out with quarterly earnings of $4.67 per share, beating the Zacks Consensus Estimate of $4.18 per share. This compares to earnings of $3.67 per share a year ago.

Zacks Investment Research • Feb 9, 2026

Medpace Holdings: Great Quarter, Stale Backlog, Full Valuation

Medpace Holdings delivered strong Q4 and FY 2025 results, beating revenue and EPS expectations, with 32% YoY revenue growth and 27% YoY EPS growth. MEDP's backlog growth remains sluggish, but a healthy book-to-bill ratio and potential sector recovery could accelerate future growth. Valuation is now fair at ~32x P/E, with a DCF suggesting modest 6% upside; disciplined share buybacks continue to support EPS growth.

Seeking Alpha • Feb 10, 2026